An article in the Japanese press is praising the quality of research in cellular therapy at the UCL within the laboratory of Prof. Etienne Sokal and at Louvain-born spin-off Promethera Biosciences.
The article on regenerative medicine, recently published in Japan’s second largest newspaper, the Asahi Shimbun, highlights the research of Prof Etienne Sokal, hepatic paediatrician at St. Luc University’s Institute of experimental and clinical research and for Promethera Biosciences in the field of liver disease treatment using stem cells. In just 4 years this young company created by Prof. Etienne Sokal has experienced a spectacular development and international recognition. In 2013, Promethera capped an exceptional fund raising level of €23,6 million thanks to the support of private investors and Belgium’s Walloon Region. Promethera Biosciences, a company specializing in the treatment of liver pathologies using stem cells, developed a flagship product, HepaStem which, when injected directly into the vein drains the liver, allowing to spare the patient from liver transplant, expensive intervention and, in certain cases, unrealizable interventions.
Pr Etienne Sokal has been invited to give a conference regarding this subject at the Meetings of the 13th Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology and Nutrition (APPSPGHAN) and 40th Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (JSPGHAN) which will take place from October 31st through November 3rd, 2013 in Tokyo.